8-K

pf11518635-8k.txt

CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

-----------

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2009

----------------

PFIZER INC.

-----------

(Exact name of registrant as specified in its charter)

Delaware 1-3619 13-5315170

-------- ------ ----------

(State or other (Commission File Number) (IRS Employer

jurisdiction of Identification Number)

incorporation)

235 East 42nd Street, New York, New York 10017

------------------------------------------------------

(Address of principal executive offices) (zip code)

Registrant's telephone number, including area code: (212) 573-2323

--------------

Not Applicable

-------------------------------------------------------------

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the filing obligation of the registrant under any of the

following provisions:

|X| Written communications pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

Pfizer Inc., a Delaware corporation (the "Company"), Wagner Acquisition

Corp., a Delaware corporation and direct wholly-owned subsidiary of the Company

("Merger Sub"), and Wyeth, a Delaware corporation ("Wyeth"), have entered into a

definitive Agreement and Plan of Merger (the "Merger Agreement") dated as of

January 25, 2009. Pursuant to the Merger Agreement and subject to the conditions

set forth therein, Merger Sub will merge with and into Wyeth (the "Merger"),

with Wyeth surviving as a wholly-owned subsidiary of the Company.

As a result of the Merger, each outstanding share of Wyeth's common

stock, other than shares of restricted stock (which will be entitled to receive

cash consideration pursuant to separate terms of the Merger Agreement), and

shares of common stock held directly or indirectly by the Company or Wyeth

(which will be cancelled as a result of the Merger), and other than those shares

with respect to which appraisal rights are properly exercised and not withdrawn,

will be converted into the right to receive $33.00 in cash (the "Cash

Consideration"), without interest, and 0.985 validly issued, fully paid and

non-assessable shares of common stock of the Company (the "Stock

Consideration"). Under the terms of the Merger Agreement, in the event that the

number of shares of common stock of the Company issuable as a result of the

Merger would exceed 19.9% of the outstanding shares of common stock of the

Company immediately prior to the closing of the Merger, the Stock Consideration

will be reduced so that no more than 19.9% of the outstanding shares of common

stock of the Company become issuable in the Merger and the Cash Consideration

will be increased by a corresponding amount.

The completion of the Merger is subject to certain conditions,

including, among others, (i) adoption of the Merger Agreement by Wyeth's

stockholders, (ii) the absence of certain legal impediments to the consummation

of the Merger, (iii) the expiration or termination of the applicable waiting

period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as

amended, and obtaining antitrust approvals in certain other jurisdictions, (iv)

subject to certain materiality exceptions, the accuracy of the representations

and warranties made by the Company and Wyeth, respectively, and compliance by

the Company and Wyeth with their respective obligations under the Merger

Agreement, (v) declaration of the effectiveness by the Securities and Exchange

Commission of the Registration Statement on Form S-4 to be filed by the Company;

and (vi) the lenders providing the Company with debt financing in connection

with the Merger shall not have declined to provide such financing at closing due

to the occurrence of a Parent Material Adverse Effect (as defined in the Merger

Agreement) or due to the Company's failing to obtain (A) an unsecured long-term

obligations rating of at least "A2" (with stable (or better) outlook) and a

commercial paper credit rating of at least "P-1" (which rating shall be

affirmed) from Moody's Investors Services, Inc. and (B) a long-term issuer

credit rating of at least "A" (with stable (or better) outlook) and a short-term

issuer credit rating of at least "A-1" (which rating shall be affirmed) from

Standard & Poor's Ratings Group (it being understood that an unsecured long

-term obligations rating of higher than "A2" and a long-term issuer credit

rating of higher than "A" shall satisfy the foregoing condition, as applicable,

irrespective of whether or not such rating(s) are subject to "negative watch" or

"negative outlook") (the "Specified Financing Condition").

Each of the Company and Wyeth has made representations and warranties in

the Merger Agreement. Wyeth has agreed to various covenants and agreements,

including, among other things (i) to conduct its business in the ordinary course

of business during the period between the execution of the Merger Agreement and

the closing of the Merger and (ii) not to solicit alternate transactions. The

Company has also agreed to various covenants and agreements, including, among

other things (i) to conduct its business in the ordinary course of business

during the period between the execution of the Merger Agreement and the closing

of the Merger and (ii) not to engage in acquisitions or share repurchases above

certain agreed thresholds. Additionally, the Company is required to reduce its

quarterly dividend to no more than $0.16 per share.

The Merger Agreement contains specified termination rights for the

parties. If the Merger Agreement is terminated in certain circumstances where

Wyeth receives an acquisition proposal that the board of directors of Wyeth

determines is, or is reasonably likely to lead to, a Superior Proposal (as

defined in the Merger Agreement), then Wyeth would be required to pay the

Company a termination fee of (i) $1.5 billion if such proposal is received

during the first 30 days following execution of the Merger Agreement or (ii) $2

billion if such proposal is received after the first 30 days following execution

of the Merger Agreement. Wyeth would also be required to pay the Company a

termination fee of $2 billion if (1) the Merger Agreement is terminated due to

either the failure of Wyeth's shareholders to approve the Merger or Wyeth's

breach of the Merger Agreement, and in each case, certain additional

circumstances occur, and (2) within twelve months following such termination,

Wyeth enters into a definitive agreement with a third party with respect to

certain extraordinary transactions or certain extraordinary transactions are

consummated. In addition, if as a result of an Intervening Event (as defined in

the Merger Agreement) Wyeth's board of directors changes its recommendation that

its shareholders approve the Merger, then the Company may terminate the Merger

Agreement, in which case Wyeth would be required to pay the Company a $2 billion

termination fee and reimburse the Company for up to $700 million of expenses

incurred by the Company in connection with the Merger.

If all conditions to the Merger Agreement are satisfied other than the

Specified Financing Condition and the Company does not consummate the Merger

within the period specified in the Merger Agreement, then the Merger Agreement

may be terminated by Wyeth, in which case the Company would be required to pay

Wyeth a termination fee of $4.5 billion.

Additionally, the Company has agreed that it will cause two current

directors of Wyeth to be appointed to the board of directors of the Company at

the closing of the Merger.

The foregoing description of the Merger Agreement and the transactions

contemplated thereby is not complete and is subject to and qualified in its

entirety by reference to the Merger Agreement, a copy of which is attached

hereto as Exhibit 2.1 and the terms of which are incorporated herein by

reference.

The Merger Agreement has been included to provide investors and security

holders with information regarding its terms. It is not intended to provide any

other financial information about the Company, Wyeth, or their respective

subsidiaries and affiliates. The representations, warranties and covenants

contained in the Merger Agreement were made only for purposes of that agreement

and as of specific dates; were solely for the benefit of the parties to the

Merger Agreement; may be subject to limitations agreed upon by the parties,

including being qualified by confidential disclosures made for the purposes of

allocating contractual risk between the parties to the Merger Agreement instead

of establishing these matters as facts; and may be subject to standards of

materiality applicable to the contracting parties that differ from those

applicable to investors. Investors should not rely on the representations,

warranties and covenants or any description thereof as characterizations of the

actual state of facts or condition of the Company, Merger Sub or Wyeth or any of

their respective subsidiaries or affiliates. Moreover, information concerning

the subject matter of the representations, warranties and covenants may change

after the date of the Merger Agreement, which subsequent information may or may

not be fully reflected in public disclosures by the Company and Wyeth.

Item 8.01. Other Events.

Financing Commitments

On January 25, 2009, the Company entered into a bridge term facility

commitment letter (the "Bridge Term Facility Commitment Letter") pursuant to

which a syndicate of banks comprised of J.P. Morgan Securities Inc., JPMorgan

Chase Bank, N.A., Banc of America Securities LLC, Bank of America, N.A.,

Barclays Bank PLC, Citigroup Global Markets Inc. and Goldman Sachs Credit

Partners L.P. (together, the "Initial Bridge Lenders") have committed to provide

a portion of the financing for the transactions contemplated by the Merger

Agreement. The Bridge Term Facility Commitment Letter provides that the Initial

Bridge Lenders will commit to provide $22.5 billion under an unsecured bridge

term facility (the "Bridge Term Facility"). The commitment is subject to various

conditions, including no Company Material Adverse Effect (as defined in the

Merger Agreement) or Parent Material Adverse Effect (as defined in the Merger

Agreement) having occurred, the maintenance by the Company of the credit ratings

set forth in the Specified Financing Condition and other closing conditions.

In addition, on January 25, 2009, the Company entered into a revolving

credit facility commitment letter (the "Revolving Credit Facility Commitment

Letter") pursuant to which a syndicate of banks comprised of J.P. Morgan

Securities Inc., JPMorgan Chase Bank, N.A., Banc of America Securities LLC, Bank

of America, N.A., Barclays Bank PLC, Citigroup Global Markets Inc. and Goldman

Sachs Credit Partners L.P. (together, the "Initial Revolving Lenders") have

committed to provide a portion of the financing for an unsecured revolving

credit facility (the "Revolving Credit Facility") that is intended to refinance

and replace an existing credit facility. The Revolving Credit Facility

Commitment Letter provides that the Initial Revolving Lenders will commit to

provide a portion of the up to $4.0 billion total commitments under the

Revolving Credit Facility and use their commercially reasonable efforts to

arrange a syndicate of lenders to underwrite the balance of the commitments

under the Revolving Credit Facility. The commitment is subject to various

conditions, including obtaining commitments for the uncommitted portion of the

Revolving Credit Facility, the Specified Financing Condition and other closing

conditions.

In connection with the syndication of the Bridge Term Facility and the

Revolving Credit Facility, the Company will provide potential lenders with the

summary descriptions for each facility, attached hereto as Exhibits 99.1 and

99.2. The summary term sheets for the Bridge Term Facility and the Revolving

Credit Facility summarize certain basic proposed terms of the facilities and are

not intended to be a definitive list of all of the terms of and conditions to

the proposed facilities. Moreover, the proposed terms and conditions set forth

in the term sheets are subject to change.

Forward Looking Statements

This document includes "forward-looking statements" within the meaning of the

safe harbor provisions of the United States Private Securities Litigation Reform

Act of 1995. Such statements may include, but are not limited to, statements

about the benefits of the proposed Merger between the Company and Wyeth,

including future financial and operating results, the combined company's plans,

objectives, expectations and intentions and other statements that are not

historical facts. Such statements are based upon the current beliefs and

expectations of the Company's and Wyeth's managements and are subject to

significant risks and uncertainties. Actual results may differ from those set

forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from

those set forth in the forward-looking statements: the possibility that the

expected synergies from the proposed Merger of the Company and Wyeth will not be

realized, or will not be realized within the expected time period, due to, among

other things, the impact of pharmaceutical industry regulation and pending

legislation that could affect the pharmaceutical industry; the ability to obtain

governmental and self-regulatory organization approvals of the Merger on the

proposed terms and schedule; the failure of Wyeth stockholders to approve the

Merger; the risk that the businesses will not be integrated successfully;

disruption from the Merger making it more difficult to maintain business and

operational relationships; the possibility that the Merger does not close,

including, but not limited to, due to the failure to satisfy the closing

conditions; the Company's and Wyeth's ability to accurately predict future

market conditions; dependence on the effectiveness of the Company's and Wyeth's

patents and other protections for innovative products; the risk of new and

changing regulation and health policies in the U.S. and internationally and the

exposure to litigation and/or regulatory actions. Additional factors that could

cause results to differ materially from those described in the forward-looking

statements can be found in the Company's 2007 Annual Report on Form 10-K,

Wyeth's 2007 Annual Report on Form 10-K and each company's other filings with

the Securities and Exchange Commission (the "SEC") available at the SEC's

Internet site (http://www.sec.gov).

Additional Information

In connection with the proposed Merger, the Company will file with the SEC a

Registration Statement on Form S-4 that will include a proxy statement of Wyeth

that also constitutes a prospectus of the Company. Wyeth will mail the proxy

statement/prospectus to its stockholders. The Company and Wyeth urge investors

and security holders to read the proxy statement/prospectus regarding the

proposed Merger when it becomes available because it will contain important

information. You may obtain copies of all documents filed with the SEC regarding

this transaction, free of charge, at the SEC's website (www.sec.gov). You may

also obtain these documents, free of charge, from the Company's website,

www.pfizer.com, under the tab "Investors" and then under the tab "SEC Filings".

You may also obtain these documents, free of charge, from Wyeth's website,

www.wyeth.com, under the heading "Investor Relations" and then under the tab

"Financial Reports/SEC Filings".

The Company, Wyeth and their respective directors, executive officers and

certain other members of management and employees may be soliciting proxies from

Wyeth stockholders in favor of the Merger. Information regarding the persons who

may, under the rules of the SEC, be deemed participants in the solicitation of

the Wyeth stockholders in connection with the proposed Merger will be set forth

in the proxy statement/prospectus when it is filed with the SEC. You can find

information about the Company's executive officers and directors in its

definitive proxy statement filed with the SEC on March 14, 2008. You can find

information about Wyeth's executive officers and directors in its definitive

proxy statement filed with the SEC on March 14, 2008. You can obtain free copies

of these documents from the Company and Wyeth using the contact information

above.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

----------- -----------

2.1 Agreement and Plan of Merger among Pfizer Inc., Wagner

Acquisition Corp. and Wyeth, dated January 25, 2009.

99.1 Summary of the Bridge Term Facility.

99.2 Summary of the Revolving Credit Facility.

SIGNATURES

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Matthew Lepore

------------------------------------------------

Name: Matthew Lepore

Title: Vice President, Chief Counsel-Corporate

Governance, and Assistant General Counsel

Dated: January 29, 2009

PFIZER INC.

FORM 8-K

CURRENT REPORT

EXHIBIT INDEX

-------------

Exhibit No. Description

----------- -----------

2.1 Agreement and Plan of Merger among Pfizer Inc., Wagner

Acquisition Corp. and Wyeth, dated January 25, 2009.

99.1 Summary of the Bridge Term Facility.

99.2 Summary of the Revolving Credit Facility.